by WolfsRoot | Oct 17, 2024 | Allgemein
Transition into clinical-stage development marks a significant corporate and R&D milestone. Munich, Germany, October 17, 2024 – SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2 antibodies, today announced...
by WolfsRoot | Jul 9, 2024 | Allgemein
The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2 strategy. Munich, Germany, July 9, 2024 SciRhom GmbH, a...
by WolfsRoot | Jun 12, 2024 | Allgemein
Munich, Germany, June 12, 2024 – SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic antibodies, announced today the approval of a clinical trial application (CTA) by the Austrian regulatory authorities (BASG/AGES) for...
by WolfsRoot | Nov 15, 2023 | Allgemein
SciRhom GmbH, a pioneering biotech enterprise specialized in developing first-in-class therapeutic antibodies, announced today the achievement of a significant milestone in its development pipeline. The company has submitted a Clinical Trial Application for its lead...
by WolfsRoot | May 12, 2022 | Allgemein
To optimize management expertise for the next phase of development, Dr. Jan Poth will assume the role of Chief Executive Officer in advancing the company’s proprietary anti-iRhom2 antibodies. Munich, Germany, May 12, 2022 – SciRhom GmbH, a therapeutic antibody...
by WolfsRoot | Apr 11, 2022 | Allgemein
SciRhom has taken the next step towards IND submission of the company’s first-in-class drug candidate for improved treatment of autoimmune diseases. Munich, Germany, April 11, 2022 – SciRhom GmbH announced today that it has nominated the anti-iRhom2 antibody it will...
Recent Comments